Background. Patients who start combination antiretroviral therapy (cART) during primary HIV-1 infection show a smaller HIV-1 latent reservoir, less immune activation and a smaller viral diversity compared to patients who start cART during chronic infection. We conducted a pilot study to test whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir monotherapy.
Background
Long term toxicity of combination antiretroviral therapy (cART) is a substantial contributor to morbidity in chronically infected HIV-1 positive individuals [1] . Nucleoside reverse transcriptase inhibitors (NRTIs) are the main reasons for ART-related toxicity. Trying to avoid NRTIs, initial randomized studies explored protease inhibitor-based monotherapy strategies. From a virological point of view, protease inhibitor-based monotherapy was clearly inferior to cART and was therefore not introduced into clinical practice [2] . However, at least in the context of more frequent viral load monitoring of a clinical trial, it did not lead to the loss of more treatment options compared with cART [3] . . Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) used as a component of preferred cART [4] . Several simplification studies were recently performed with dolutegravir as a main active drug [5, 6] .
A dolutegravir-based dual therapy regimen in combination with lamivudine or rilpivirine shows promising results [5, 7] . In contrast, three randomized controlled trials exploring the efficacy of dolutegravir-based monotherapy revealed inferiority compared to cART [6, 8, 9] . Notably, all protease inhibitor and dolutegravir simplification studies were conducted in patients initiating cART during chronic HIV-1 infection. Importantly patients who initiated cART during the early phase of HIV-1 infection harbor a markedly reduced HIV-1 reservoir [10, 11] and show low viral diversity [12, 13] .
The Zurich Primary HIV Infection Study (ZPHI) is an ongoing observational study enrolling individuals with documented primary HIV infection, i.e. individuals identified within 180 days after estimated date of infection [14] . Since 2002, immediate start of cART is offered to the ZPHI participants. We hypothesized that individuals who start cART early have a smaller HIV-1 reservoir and, therefore, are the best candidates to maintain viral suppression after switching to dolutegravir monotherapy comparable to that seen under continued cART.
We tested our hypothesis in a pilot study consisting of individuals who had been successfully treated with cART for at least 48 weeks since primary HIV-1 infection before being randomized to dolutegravir monotherapy.
Methods

Study design and patients
All patients enrolled in this trial have a documented primary HIV-1 infection and the majority of them (85%) are enrolled in the Zurich Primary HIV Infection Study (ZPHI), an open label, non-randomized, observational, multi-site study (http://clinicaltrials.gov, ID 5 NCT00537966) [14] . All patients were participating in the Swiss HIV cohort study, a long-term observational study [15] . Primary HIV-1 infection was defined as published elsewhere [16] .
In this randomized, open-label, non-inferiority trial, we recruited patients aged ≥18 years with a primary HIV-1 infection and no previous antiretroviral treatment failure, no prior treatment interruption, no major resistance mutations to INSTIs according to the Stanford algorithm [17] , an HIV-1 RNA of less than 50 copies/mL plasma for 48 weeks or longer, and a negative hepatitis B virus surface antigen. Patients with documented resistance to any NRTI, non-NRTI or protease inhibitors were allowed to be included. Exclusion criteria were pregnancy or breastfeeding, use of contraindicated drugs to dolutegravir, and previous intolerance to dolutegravir.
We obtained ethics committee approval at all participating centers in accordance with the principles of the 2008 Declaration of Helsinki. All participants gave their written informed consent before undergoing any study procedure. This study is registered with ClinicalTrials.gov, number NCT02551523.
Study procedures
Patients in the monotherapy group were simplified to oral dolutegravir 50 mg once daily, and those in the cART group continued their current regimen consisting of either an INSTI, a boosted protease inhibitor, or NNRTI, in combination with two NRTIs. We assessed HIV-1 RNA in the plasma, using the COBAS AmpliPrep/TaqMan HIV-1 Test Vs 2.0 with a limit of detection ≤20 HIV-1 RNA copies per mL plasma. We measured total HIV-1 DNA in peripheral blood mononuclear blood cells (PBMCs) using an in-house digital droplet PCR assay at baseline and week 48. We assessed markers for proximal renal tubulopathy, and lipid levels at baseline and at week 48. All patients were asked for a lumbar puncture at baseline, and at week 48. ART drug levels were measured in plasma and in cerebrospinal fluid (CSF) at week 0 and week 48. The study procedures are described in detail in the Supplementary Appendix.
Outcomes
The primary endpoint was non-inferiority of the virological response between treatment groups, defined as the proportion of patients without a virological failure on or before week 48. Virological failure was defined as two consecutive viral loads (14 days or longer but not more than 30 days apart) above 50 HIV-1 RNA copies per mL plasma. The window of visit was ±4 weeks, thus a HIV-RNA value obtained between weeks 44-52 was included in the primary efficacy analysis. If the HIV-1 RNA measurement was missing at week 48, we included the last documented HIV-1 RNA measurement prior to week 48 in the primary efficacy analysis (last observation carried forward principle).
Secondary endpoints were quantification of total HIV-1 DNA in PBMCs, central nervous system (CNS) virological escape (defined as less than 40 HIV-1 RNA copies per mL CSF), frequency of blips (defined as one viral load between 50 and 400 followed by a viral load below 50 HIV-1 RNA copies per mL plasma within 30 days), number of adverse events and serious adverse events, changes in CD4 cell count, new onset of proximal tubular renal dysfunction (defined as pathological tubulopathy-markers according to Fux et al. [18] ), changes in lipid profiles, withdrawing consent and lost-to-follow-up, switching assigned treatment for any cause before and after simplification.
Statistical analysis
The study was powered to detect non-inferiority at 48 weeks, assuming a response of 95% in both groups. Thus, to show non-inferiority at a margin of 10% at week 48, with a significance value of 5% and a power of 80%, we estimated the sample size at 138 assessable patients. The final study population consisted of 101 patients because of the lower rate of recruitment as anticipated during the last few months of the study. The decision to stop recruitment was taken by the sponsor H.F.G. and was independent of any efficacy analysis. The static unstratified multi-block randomization with multiplier 3 integrated in SecuTrial (http://www.secutrial.com/en/) was used to allocate patients in a 2:1 ratio to monotherapy with dolutegravir or continuation of cART including three patients per block with computer-generated random number sequences. More details are provided in the Supplementary Appendix.
Results
Out of 430 patients assessed for study enrolment, 101 (23.4%) were eligible for the study and agreed to participate ( Figure 1 ). Between November 30, 2015, and March 10, 2017, we randomized 101 patients in a 2:1 ratio, allocating 68 [67%] to dolutegravir monotherapy and 33 [33%] to cART ( Figure 1 ). Baseline characteristics are depicted in Table 1 .
Efficacy
In the per-protocol population, all 67 patients in the monotherapy group and all 32 patients in the cART group had a virological response on or before week 48 ( Figure 2 ). One patient in the monotherapy group was excluded during the study due to a major protocol violation: this patient did not fulfill the definition of a primary HIV-1 infection but this information was missed at screening and the patient was therefore incorrectly enrolled into the study.
Detailed information on this patient is provided in the Supplementary Appendix. In the cART group, one patient moved abroad at week 26 ( Figure 1 ). Non-inferiority was shown at the pre-specified level of 10%, as the difference in efficacy between monotherapy and cART was similar. We also noted non-inferiority in the intention-to-treat population (67/68, 98·5% dolutegravir versus 33/33, 100% cART; difference 1·47%, 95%-CI [-100%, 6·85%]).
The patient in the cART group who moved abroad was counted as success in the intention-to-treat analysis, assuming that this patient maintained viral suppression after study discontinuation. This assumption led to a more conservative approach in interpreting the data.
Figure 2
Virological response at week 48 defined as absence of virological failure in first 48 weeks for the per-protocol and intention-to-treat populations among the dolutegravir (DTG) monotherapy group (orange bars) and the standardof-care combination antiretroviral therapy (cART) group (light blue bars). Virological failure is defined as 2 consecutive human immunodeficiency virus type 1 RNA >50 copies/mL in plasma. The proportion of patients with virological response in each group is depicted in the lower plot, while the upper plot summarizes the difference in proportions of patients with virological response between the study arms. The black symbols depict the proportions and the respective differences, and the error bars indicate the 95% exact confidence intervals (CIs). The light green shading represents the area of 95% CI upper bound for which the noninferiority is concluded. The CIs for the single proportions are the Clopper-Pearson (exact) CIs.
HIV-1 reservoir
We measured total HIV-1 DNA in PBMCs at baseline and at week 48. The median log10 total HIV-1 DNA change from baseline to week 48 in the dolutegravir monotherapy arm was -0·16 compared to -0·10 in the cART arm (pvalue 0·312) ( Figure 3 ).
Figure 3
Total human immunodeficiency virus type 1 (HIV-1) DNA quantification from baseline compared to week 48 stratified by DTG monotherapy (orange) vs cART (blue). The shaded areas depict the distribution of the HIV-1 DNA values in both groups at baseline and at week 48. The dashed lines connect the medians of log10 HIV-1 DNA values at baseline and week 48. Abbreviations: cART, combination antiretroviral therapy; DTG, dolutegravir.
There was a significant decay of the total HIV DNA in the monotherapy arm at week 48 compared to baseline (pvalue = 0.0004). The HIV DNA decay among the cART group did not reach statistical significance (p-value = 0.0982). The total HIV-1 DNA levels for single patients are shown in the supplementary figure 1. We recorded viral load blips not leading to treatment interruption in 1 (1·5%) of 68 patients in the monotherapy group (607 visits) and 1 (3·0%) of 33 patients (124 visits) in the cART group (p-value <0·001 from the Poisson regression for rate of blips) ( Figure 4 ). The median change in CD4 cell count from baseline was 74 cells per μL blood (interquartile range [IQR] -32 to 198) for monotherapy and 24 cells per μL blood (IQR -144 to 116) for cART (p=0·124) (supplementary figure 2). All patients in both study groups were adherent to study drugs for the 48 weeks of study.
Figure 4
Viral blips stratified by dolutegravir (DTG) monotherapy vs standard-of-care combination antiretroviral therapy (cART). One patient in the DTG monotherapy group experienced a single blip at week 20, and 1 patient in the standard-of-care cART group had 2 blips. The light colors show the human immunodeficiency virus type 1 (HIV-1) RNA levels above the limit of detection (20 copies/mL; dotted light gray line), which were not classified as viral blips (>50 copies/mL; depicted by dashed gray line). Among the 13 patients with at least 1 HIV-1 RNA measurement above 20 copies/mL, four patients were from the cART group (3 participants with a single level >20 copies/mL and 1 with 3 HIV-1 RNA levels >20 copies/mL). In the DTG monotherapy group, one patient had 3 HIV-1 RNA levels >20 copies/mL, one patient had 2 HIV-1 RNA levels >20 copies/mL, and seven patients had a single HIV-1 RNA level above 20 copies/mL. The failing patient was excluded from this analysis.
Plasma and CSF dolutegravir levels assessment
At baseline, 23 (33·8%) patients in the monotherapy group and 14 (42·4%) in the cART group agreed to have a lumbar puncture. At week 48, 10 (14·9%) patients in the monotherapy group and 2 (6·2%) in the cART group agreed to have a second lumbar puncture. The CSF viral load was undetectable in all sampled patients at all times tested ( Figure 5 ). Plasma and CNS concentration of dolutegravir measurements at week 0, 4, and week 48 are depicted in Figure 6 . According to the percentile curves of Aouri et al. [19] , 3·7% (n=6) of dolutegravir concentrations in the plasma were below the 10th percentile.. All dolutegravir concentrations in CSF exceeded the in vitro IC 50 for wild-type HIV (0.2 ng/mL) [20] .
Figure 5
Human immunodeficiency virus type 1 (HIV-1) RNA measurements in the cerebrospinal fluid (CSF). Patients were asked to have a lumbar puncture performed at baseline and at week 48. The patient with virological failure at week 36 was the only patient who received an additional lumbar puncture at week 41. Orange and blue circles depict the single HIV-1 RNA measurements in CSF for the dolutegravir (DTG) monotherapy and standard-ofcare combination antiretroviral therapy (cART) groups, respectively. The dotted gray line represents the detection limit. 
Discussion
Our Early Simplified randomized clinical trial shows non-inferiority of dolutegravir monotherapy compared to cART in patients who initiated cART during primary HIV-1 infection and showed viral suppression for at least 48 weeks prior to switching to dolutegravir monotherapy. No virological failure occurred in the per-protocol population. This is in sharp contrast to previous randomized trials that revealed inferiority of dolutegravir monotherapy compared to cART [6, 8, 9] : the virological failure rate was so high, that all studies were prematurely discontinued. Furthermore, emergence of drug resistance to currently licensed INSTIs occurred among patients failing on dolutegravir monotherapy [6, 8, 9] . Data from non-randomized, partly retrospective clinical studies are less clear [21, 22] . Some studies show maintained viral suppression after switch from cART to dolutegravir monotherapy, others do not.
Notably, all prior dolutegravir monotherapy studies were conducted in patients who started their first cART during chronic HIV-1 infection. In contrast, we conducted our simplification study in patients who initiated cART during primary HIV-1 infection and were virologically suppressed for at least 48 weeks prior to entering the study. We chose this strategy because patients with early ART initiation have an approximately tenfold lower latent HIV-1 reservoir [10, 11] , less immune activation [23] , and smaller viral diversity [12, 13] compared to patients who initiated cART during chronic infection. Our à priori hypothesis was that these properties would enable sustained virological suppression after simplification to dolutegravir monotherapy. With our novel approach to stratify patients for a dolutegravir monotherapy according to their time of HIV-1 infection at start of first cART, all patients maintained viral suppression. A potential explanation is that among patients with a small HIV-1 latent reservoir, the stochastic chance of an activation of latently HIV-1 infected cells is less likely, compared to patients with a large reservoir. Supporting this, the HIV-1 latent reservoir size predicted virological failures in the randomized controlled dolutegravir monotherapy trial conducted by Wijting el al [6, 24] . Moreover, the large variation in time to virological failure in this study suggests that stochastic reactivation could be the mechanism for failure [25] . In addition, a low nadir CD4 cell count and thus a surrogate for length of untreated HIV infection and a big reservoir size was predictive for virological failure in the MONCAY trial [9] . In addition, it has been shown that patients treated early with cART have less immune activation compared to those treated during chronic HIV-1 infection [23] . This may translate to a lower extent of activation of latently HIV-1 infected cells. Finally, early treated patients maintain a lower viral diversity in blood as well as sanctuary sites -such as gut-associated tissue and the CNS [12, 26] -and, therefore, viral escape is less likely to occur.
To assess potential changes in the HIV-1 latent reservoir on dolutegravir monotherapy, we measured total HIV-1 DNA levels in PBMCs from patients at baseline and at week 48 and found that there was a comparable slight decay in the total HIV DNA load in both groups. Our finding that the total HIV DNA load in the monotherapy group did not increase over time suggests that the HIV-1 latent reservoir was not replenished on dolutegravir monotherapy. Supporting this, the frequency of viral blips was very low in both treatment groups, but even lower in the dolutegravir monotherapy group despite a much higher sampling frequency.
To investigate whether patients on dolutegravir monotherapy are at increased risk for CNS escape, i.e., ongoing viral replication in the CNS in the presence of suppressed viremia in the plasma, we performed longitudinal lumbar punctures and measured the HIV-1 RNA in the CSF in a subset of patients at baseline and at week 48. In all CSF samples, HIV-1 RNA was not detected above the limit of quantification of 40 HIV-1 RNA copies/mL CSF at baseline (n= 37) and at week 48 (n=12). We also measured dolutegravir drug levels in the CSF as a proxy for CNS penetration. In line with previous work [20] , we found that in all patients on dolutegravir monotherapy or on dolutegravir-containing cART the concentrations in CSF exceeded the in vitro IC 50 for wildtype HIV-1. This finding suggests that in our specific patient population dolutegravir monotherapy is able to achieve therapeutic concentrations in the CNS and to prevent CNS escape in this sanctuary site.
The main goal of ART simplification is to reduce long-term toxicity associated with ART and to reduce costs. Indeed, almost all currently licensed antiretroviral drugs showed significant toxicity in post-marketing surveillance studies [27] . Thus, simplifying a patient to dolutegravir monotherapy could be a reasonable strategy to reduce long-term toxicity and daily pill counts in some patients. Although we did not find significant changes from baseline in lipid levels and proximal tubulopathy markers, it is possible that the follow-up time of 48 weeks was too short to detect clinically meaningful changes.
The strength of our study is that we tested a new and clear hypothesis for the first time: Do viral and immunological properties resulting from early cART initiation translate into successful viral suppression after switch to dolutegravir monotherapy? We selected our patients based on a distinct clinical phenotype and combined our treatment intervention with several laboratory measurements to investigate the potential positive and negative impact of a dolutegravir monotherapy on toxicity-markers, the HIV-1 reservoir, and potential CNS compartmentalization. A limitation of our study is that we were not able to recruit the targeted number (n=138) of patients that was calculated for the targeted 80% power. Therefore, the study-results rely on a small number of patients. The major reason for the low recruitment was the high frequency of patient's visits we requested for safety reasons: close HIV-1 RNA monitoring was performed in the dolutegravir monotherapy arm during the first 6 months to detect a potential virological failure as early as possible. Even though we enrolled less patients than originally anticipated, non-inferiority could be demonstrated. Since the power in non-inferiority studies guarantees that the probability of showing non-inferiority when the new treatment is indeed non-inferior to the control is sufficiently high, the post study power is meaningless in case of significant results. Another possible limitation is the short follow-up period of 48 weeks. To address this limitation, we prolonged the study-duration to four years at the time when the first studies reported a large number of patients failing on dolutegravir monotherapy. Finally, one potential limitation is that the frequent HIV-1 RNA measurements during the first 24 weeks might have increased adherence in the monotherapy group. However, these patients only came for short additional blood draw visits with the study nurse without counselling and adherence as measured by pill counts upon visits did not differ between groups.
Our pilot study has potential implications for the management of HIV-1 infected patients: Our results suggest that success of simplification strategies using dolutegravir monotherapy is likely governed by early start of treatment with subsequent low latent HIV-1 reservoir size, low viral diversity and low immune activation. It suggests that trials evaluating simplification strategies should stratify between patients first treated during primary and chronic infection. This is of particular relevance because today all HIV-1-infected patients should be treated immediately regardless of their CD4 count [28] and thus the fraction of patients treated early after infection most likely will increase. As our data shows, these patients may be potentially over treated for decades if patient population stratification is not performed in future simplification trials. Recent studies show that simplification with boosted protease inhibitors or dolutegravir each combined with lamivudine seem to work [29, 30] , supporting the possibility that future ART could be personalized much more than it is today. One can even imagine that in the future, HIV-1 maintenance therapies will be started by measuring the size of the latent reservoir, e.g. by proviral HIV-1 DNA or other future assays, and might be predictive in whom monotherapy can be applied. Therefore, more prospective controlled future simplification studies are needed that use stratification strategies according to the time of HIV infection and start of first cART guided by measurements of the latent reservoir. In addition, longer follow-up is important as for all prospective clinical cART trials because failure was observed after week 48 in several studies [6, 9] . 
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Study procedures:
We shown. We assessed markers for proximal renal tubulopathy, and lipid levels at baseline and at week 48, respectively. All patients were asked for a lumbar puncture at baseline, and at week 48. ART drug levels were measured in plasma and in cerebrospinal fluid (CSF) at week 0 and week 48. In patients randomized to dolutegravir monotherapy, drug levels were additionally measured at week 4 in the plasma, and at time of confirmed virological failure. We assessed adherence on the basis of tablet count done when patients returned their drug bottles at each visit. We defined non-adherence as a proportion less than 95% at week 48.
Patient with major protocol violation
One patient from the monotherapy group was excluded from the per-protocol analysis because the patient fulfilled the criteria of a major protocol violation: he didn't have a documented primary HIV-1 infection at the time when he started first cART but this information was missed at the screening visit. Thus, this patient was incorrectly included in the Early Simplified Trial. This patient experienced a virological failure during the study: 382 and 672 HIV-1 RNA copies per mL plasma were detected at weeks 36 and 40, respectively. No new RAMS were detected at week 36. The RAMs 138A and 88S associated with decreased susceptibility to rilpivirine and atazanavir respectively, detected prior to any cART, were detected again at week 40. Plasma virus was re-suppressed with the same cART regimen (dolutegravir/abacavir/lamivudine) prior to simplification. Assessment of HIV-1 RNA in the CSF at time of virological failure showed a suppressed viral load <40 copies/mL and the dolutegravir drug levels of this patient measured in the plasma and in the CSF were above the IC 50. An extensive medical chart review revealed that this patient was a late presenter at the time of HIV-1 diagnosis in 2004, with a high viral load and a febrile illness compatible with acute retroviral syndrome and recent risk exposure. A fully converted western blot became available later. The CD4 cell count at the first visit was 127 cells/mL (12%) and remained low at 265 cells/mL (30%) 12 months after initiation of combination antiretroviral therapy.. We performed a retrospective assessment of the infection timing by calculating the ambiguous nucleotide score developed by Kouyos et al. from the baseline sample in 2004: the score was 2.46% (cut-off <0.5%) and therefore compatible with a duration of infection of more than 12 months at the time when the patient started his first cART. Taken all the available laboratory measurements together, the patient was misclassified as having a primary HIV-1 infection at that time.
When stratifying HIV-1 DNA levels from all patients in quartiles, the failing patient's baseline load was classified in the 4 th and highest quartile
Statistical analysis
We defined three populations for the analysis: i) the intention-to-treat population, which includes all randomly allocated patients; ii) the per-protocol population, which consists of all randomly allocated patients except for those with major protocol violations, never exposed patients, and those with two or more missed consecutive study visits (i.e., lost-to follow-up before or at week 48); and iii) the safety population, which consists of all participants who received at least one dose of the study drug. We used a non-inferiority margin of 10% to assess the primary outcome, i.e., upper bound of the one-sided 95% CI of the difference in virological response between triple treatment and monotherapy group was no more than 10%. We chose this margin because it was the most consistently used for non-inferiority trials of cART at the time of the design of the study. We analyzed the primary objective in the intention-to-treat population as a sensitivity analysis.
We used the Mann-Whitney test to compare continuous variables, the Fisher's exact test to assess the association between categorical variables and the Poisson regression to compare the viral blip rates. Patients with missing values at either baseline or week 48 were excluded from the analysis of the secondary outcomes. Custom written R-scripts were used to construct the exact confidence intervals to test the non-inferiority of the monotherapy (see supplementary material). The remaining statistical analyses were carried out in R (version 3.4.3) using the existing functions.
The PDF file (Exact_confidence_interval_functions_and_scripts.pdf) summarizes the functions, scripts and references used to construct the exact confidence intervals for the primary outcome. The R-file Exact_CI_functions.R contains the implementation of all the functions needed to construct the confidence intervals. The confidence intervals for the primary outcome from this study can be reproduced by running the Confidence_intervals_primary_outcome.R script within the project CI_primary_outcome.Rproj.
